Peptide and Nucleotide Therapeutics

1. Development and characterization of synthetic peptide drugs for targeted cancer therapy.
2. Formulation and stability studies of nucleotide-based drugs for treating rare genetic disorders.
3. Study on peptide-based inhibitors to combat antimicrobial-resistant bacterial strains.
4. Development of efficient delivery systems for RNA-based therapeutics in viral infections.
5. Investigation of cell-penetrating peptides for intracellular delivery of therapeutic molecules.
6. Stability optimization of cyclic peptides for use in chronic autoimmune diseases.
7. Role of peptide conjugates in enhancing receptor-specific drug delivery.
8. Comparative analysis of synthetic and natural peptides for antimicrobial applications.
9. Study on nucleotide-based vaccines and their role in combating emerging infectious diseases.
10. Development of therapeutic peptide scaffolds for accelerated wound healing.
11. Investigation of peptide therapeutics in managing type 2 diabetes: Formulation and efficacy.
12. Application of antisense oligonucleotides for correcting genetic mutations in inherited diseases.
13. Formulation development of CRISPR-Cas9 ribonucleoprotein complexes for gene editing.
14. Evaluation of peptide-based drug formulations for neurodegenerative diseases.
15. Optimization of lipid nanoparticles for delivering siRNA-based therapeutics to the liver.

Biological Drug Delivery Systems

16. Development of polymeric nanoparticles using biological polymers for cancer drug delivery.
17. Investigation of exosome-based drug delivery systems for targeted brain therapies.
18. Study on alginate-based hydrogels for controlled protein and peptide drug release.
19. Formulation of liposomal drug delivery systems for hydrophilic biological drugs.
20. Development of collagen-based drug delivery systems for regenerative medicine.
21. Comparative evaluation of chitosan and gelatin nanoparticles for delivering biomolecules.
22. Optimization of biodegradable microspheres for sustained protein drug delivery.
23. Study on hybrid lipid-polymer nanoparticles for dual drug delivery.
24. Investigation of biologically derived hydrogels for delivering stem cell-derived products.
25. Development of biocompatible drug delivery systems using silk fibroin for chronic diseases.
26. Role of nanosponges in delivering biologics across physiological barriers.
27. Optimization of microfluidic methods for producing biological nanoparticles.
28. Study on erythrocyte-based carriers for delivering biological therapeutics.
29. Design of bioinspired vesicles for oral delivery of insulin.
30. Comparative stability studies of biologic-loaded polymeric nanoparticles under Indian climatic conditions.

Antimicrobial Resistance

31. Investigation of antimicrobial peptides for combating multidrug-resistant pathogens.
32. Study on the development of phage therapy as an alternative to antibiotics in bacterial infections.
33. Role of biofilm-targeted peptides in preventing drug-resistant infections.
34. Development of nanoparticle-based antibiotic formulations for treating resistant tuberculosis.
35. Study on the synergistic effect of peptide antibiotics with conventional antimicrobials.
36. Development of CRISPR-based tools for targeting antibiotic resistance genes.
37. Investigation of quorum-sensing inhibitors for tackling bacterial resistance.
38. Comparative analysis of nanozymes and antimicrobial peptides in managing biofilm infections.
39. Formulation and evaluation of hybrid drug delivery systems for antimicrobial agents.
40. Role of efflux pump inhibitors in overcoming antibiotic resistance in bacterial infections.

Bioprocess Engineering and Technology

41. Optimization of upstream fermentation processes for large-scale monoclonal antibody production.
42. Study on the role of bioreactors in enhancing the yield of therapeutic proteins.
43. Development of cost-effective bioprocesses for producing biosimilars in India.
44. Investigation of continuous bioprocessing for large-scale production of biologics.
45. Application of perfusion bioreactors in stem cell-based therapy manufacturing.
46. Optimization of purification techniques for recombinant proteins in Indian industries.
47. Role of biocatalysts in improving process efficiency for pharmaceutical intermediates.
48. Study on scalable microbial fermentation for the production of vaccines.
49. Development of advanced downstream processing methods for high-purity biologics.
50. Comparative analysis of single-use versus stainless steel bioreactors in Indian biopharmaceutical facilities.
51. Study on process analytical technologies (PAT) for ensuring bioprocess consistency.
52. Investigation of the role of disposable chromatography systems in biologics manufacturing.
53. Formulation of recombinant protein therapeutics using continuous downstream processing.
54. Development of bioprocess control systems using artificial intelligence.
55. Study on challenges in large-scale biosimilar production under Indian regulatory guidelines.

Drug Discovery and Development

56. Application of structure-based drug design in discovering protein inhibitors.
57. Development of high-throughput screening methods for biologic drug discovery.
58. Role of computational tools in predicting stability of therapeutic proteins.
59. Study on the identification of novel targets for antibody-drug conjugates.
60. Application of fragment-based drug discovery in peptide-based drugs.
61. Investigation of lead optimization techniques for biologic drug candidates.
62. Development of predictive in silico tools for protein-protein interaction inhibitors.
63. Study on advanced screening methods for biologics targeting autoimmune diseases.
64. Discovery of novel ligands for enhancing the efficacy of nucleotide therapeutics.
65. Role of artificial intelligence in accelerating drug discovery pipelines for biologics.
66. Study on the impact of molecular docking simulations in designing enzyme inhibitors.
67. Development of rational approaches for stabilizing therapeutic monoclonal antibodies.
68. Optimization of preclinical studies for evaluating biologic drug candidates.
69. Identification and validation of biomarkers for biologics targeting cancer.
70. Application of molecular dynamics simulations in designing peptide drugs.